Richard Pencek

Summary

Affiliation: Amylin Pharmaceuticals
Country: USA

Publications

  1. pmc Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
    Leigh MacConell
    Amylin Pharmaceuticals, LLC, San Diego, CA, USA
    Diabetes Metab Syndr Obes 6:31-41. 2013
  2. pmc Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
    R Pencek
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Int J Clin Pract 66:1021-32. 2012
  3. doi Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index
    Richard Pencek
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Postgrad Med 124:21-32. 2012
  4. doi Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications
    Richard Pencek
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Postgrad Med 124:33-40. 2012
  5. doi Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide
    Richard Pencek
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocr Pract 18:227-37. 2012
  6. pmc Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
    Kristin Taylor
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    BMC Endocr Disord 11:9. 2011
  7. pmc Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
    Julia A Gaebler
    Amylin Pharmaceuticals, Inc, San Diego, CA, USA
    Vasc Health Risk Manag 8:255-64. 2012

Collaborators

  • Yan Li
  • Byron J Hoogwerf
  • James Malone
  • Marc Cohen
  • Leigh MacConell
  • David Maggs
  • Julia A Gaebler
  • Jenny Han
  • Kristin Taylor
  • Lisa Porter
  • Gerardo Soto-Campos
  • Amy Blickensderfer
  • Peter Alperin
  • Matthew Wintle
  • Barbara Peskin
  • Brandon Walsh
  • Kate Gurney
  • Michael Trautmann

Detail Information

Publications7

  1. pmc Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
    Leigh MacConell
    Amylin Pharmaceuticals, LLC, San Diego, CA, USA
    Diabetes Metab Syndr Obes 6:31-41. 2013
    ..Here, the efficacy and safety of treatment with ExQW for 3 years are described...
  2. pmc Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
    R Pencek
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Int J Clin Pract 66:1021-32. 2012
    ..The purpose of this pooled analysis was to evaluate the efficacy and tolerability of exenatide once weekly (EQW) in patients with type 2 diabetes grouped into subpopulations by key demographic characteristics...
  3. doi Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index
    Richard Pencek
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Postgrad Med 124:21-32. 2012
    ..The purpose of this pooled analysis was to evaluate the safety and efficacy of exenatide BID in patients stratified by various demographic characteristics...
  4. doi Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications
    Richard Pencek
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Postgrad Med 124:33-40. 2012
    ..In this pooled analysis, the efficacy and tolerability of exenatide once weekly (EQW) in patients categorized by baseline concomitant glucose-lowering therapy were evaluated...
  5. doi Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide
    Richard Pencek
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocr Pract 18:227-37. 2012
    ..To explore, by post hoc analyses of pooled data, the efficacy and safety of the use of exenatide twice daily (BID) in patients stratified by baseline glucose-lowering therapies...
  6. pmc Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
    Kristin Taylor
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    BMC Endocr Disord 11:9. 2011
    ..abstract:..
  7. pmc Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
    Julia A Gaebler
    Amylin Pharmaceuticals, Inc, San Diego, CA, USA
    Vasc Health Risk Manag 8:255-64. 2012
    ..We simulated potential effects of ExQW on vascular complications, survival, and medical costs over 20 years versus standard therapies...